Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bristol-myers squibb
4
×
life sciences
national blog main
national top stories
san diego blog main
san diego top stories
san francisco blog main
biotech
boston blog main
boston top stories
clinical trials
new york blog main
new york top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
cell therapy
detroit blog main
detroit top stories
diagnostics
genfit
gilead sciences
immunotherapy
indiana blog main
indiana top stories
medicare
merck
national
nivolumab
nonalcoholic steatohepatitis
novartis
pembrolizumab keytruda
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
What
drug
4
×
new
4
×
bio
nash
roundup
advantages
approval
approved
athena
bar
biogen’s
biopharmaceutical
biotech
brings
cancer
ceo
chief
companies
convo
countouriotis
data
disease
earlier
expect
failures
fatty
financing
gamble
gets
horizon
intercept
known
littered
liver
market
marketed
medco’s
medical
medicine
mezzanine
Language
unset
Current search:
new
×
" bristol-myers squibb "
×
drug
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
